Home » Newsletters » BioWorld Science

BioWorld Science

April 14, 2015

View Archived Issues

Researchers describe novel RNAi-based bone anabolic strategy

SNP in ARNT2 gene linked to Asperger's syndrome

REGENXBIO licenses vector delivery technologies for mucopolysaccharidosis gene therapies

Novel assay for DNA methylation predicts outcome in AML patients

Teijin Pharma develops bifunctional M3 antagonist and beta2-agonist compounds

Pierre Fabre and CNRS patent DNMT inhibitors

Scientists describe IMP3 expression and chromosome 12p abnormalities in PMTT

Novel RORgt modulators identified for inflammatory diseases

Heptares Therapeutics describes discovery of mGlu5 receptor negative allosteric modulator

The Scripps Research Institute receives NCI grant to target Hippo-YAP pathway

Hydra Biosciences and Boehringer Ingelheim collaborate on TRP inhibitors for renal diseases

Voyager Therapeutics completes financing to fund AAV gene therapy development

Neothetics initiates phase III trials of LIPO-202 for reduction of subcutaneous abdominal fat

Ichor and Janssen to develop DNA vaccines for chronic HBV infection

Berg and collaborators aim to discover first biomarker for pancreatic cancer

AEternaZentaris plans confirmatory phase III trial of Macrilen in GHD diagnosis

Sthamin1 as a biomarker to distinguish ESS and ULMS from LM

Midatech and Dana-Farber Cancer Institute to collaborate on glioblastoma nanomedicines

Merck & Co. discloses HIV integrase inhibitors

Toray reports new analgesics

The CHDI Foundation discloses KMO inhibitors

University of Cologne presents apoptosis-inducing compounds

MolMed exercises option right on San Raffaele Hospital's CAR-CD44v6 project

Phase IIb trial of Nefecon for primary IgA nephropathy meets primary endpoint

Bayer expands copanlisib program with three new trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...